首页> 外文期刊>American journal of therapeutics >Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats.
【24h】

Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats.

机译:他汀类药物改善链脲佐菌素诱导的糖尿病大鼠的肾小球通透性变化。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: Statins reduce albumin excretion rate and retard the progression of diabetic nephropathy. Whether statins alter size selectivity of glomerular filtration in diabetic rats is not known. METHODS: The creatinine clearance and the permeability of glomeruli to a group of fluorescein isothiocyanate dextrans of varying molecular weights were studied in rats with streptozotocin-induced diabetes that were treated with either 10 mg/kg rosuvastatin or simvastatin for 5 weeks. RESULTS: Statin therapy did not significantly alter the increased creatinine clearance in diabetic rats. During the 5 hours of urine collection there was near-complete filtration of 4-, 10-, and 20-kD dextrans in all rat groups studied. The filtration of 70- and 40-kD dextrans was significantly increased in diabetic rats after 5 weeks of diabetes. Rosuvastatin but not simvastatin was associated with partial normalization of glomerular filtration of the 70- and 40-kD dextrans. Treatment with mevalonate (150 mg/kg in drinking water for 5weeks) reversed the favorable effects of rosuvastatin on glomerular permeability. CONCLUSIONS: Statin treatment of rats with streptozotocin-induced diabetes ameliorates glomerular permeability changes. The favorable effect of rosuvastatin is probably related to the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, because mevalonate treatment reversed the favorable effects of rosuvastatin.
机译:目的:他汀类药物可降低白蛋白排泄率并延缓糖尿病性肾病的进展。他汀类药物是否会改变糖尿病大鼠肾小球滤过的大小选择性,尚不清楚。方法:在链脲佐菌素诱发的糖尿病大鼠中研究了肌酐的清除率和肾小球对一组不同分子量的荧光素异硫氰酸酯右旋糖酐的渗透性,并用10mg / kg瑞舒伐他汀或辛伐他汀治疗了5周。结果:他汀类药物疗法并没有明显改变糖尿病大鼠肌酐清除率的增加。在收集尿液的5个小时内,所有研究的大鼠组中的4-,10-和20-kD右旋糖酐几乎完全过滤。糖尿病5周后,糖尿病大鼠中70kD和40kD葡聚糖的过滤明显增加。罗苏伐他汀而不是辛伐他汀与70-kD和40-kD葡聚糖的肾小球滤过的部分正常化有关。用甲羟戊酸酯治疗(在饮用水中150 mg / kg持续5周)可逆转瑞舒伐他汀对肾小球通透性的有利作用。结论:他汀类药物治疗链脲佐菌素诱导的糖尿病大鼠可改善肾小球通透性变化。罗苏伐他汀的有利作用可能与3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶的抑制有关,因为甲羟戊酸处理逆转了罗苏伐他汀的有利作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号